SSRI CHINA news

The Chinese government has officially announced the public holidays for 2023.

• January 1-2 (New Year)
• January 21-27 (Chinese New Year)
• April 5 (Ching Ming Festival)
• April 29-May 3 (Labor Day Holidays)
• June 22-24 (Dragon Boat Festival)
• September 29-October 6 (Mid-Autumn Festival & National Day)

• SSRI CHINA moves to a new office.

• B406, Jinpu international building,
• No.21 Chifeng Street, Jinpu New Area, Dalian, 116600
• +86 (0)411 8817 6603

Social Survey Research Information Co., Ltd. and M3, Inc. launched PatientsMap 2022CN (China 2022 version) on March 31, 2022.The data were obtained from a survey of member physicians on a portal site for medical professionals operated by Medlive.cn, an M3 Group company, with 11,000 physicians responding online.

In the survey, physicians were asked whether they have received sales rep visits from manufacturers. The survey was conducted from the end of last year to the beginning of March of this year, and analysis was performed based on an understanding that the results were obtained during a near normal period of time, when the spread of COVID-19 was relatively under control.

The results showed that major Western companies ranked at the top in many specialties, in particular, with AstraZeneca having the highest rate of sales rep visits in many specialties. While in oncology, three of the top five companies were local Chinese companies.

On March 31st, 2022, SSRI and M3 launched the updated version of PatientsMap China.

PatientsMap is a database product which uncovers the types of diseases that various specialists see, and the monthly patient volume for each disease. It also includes data for sales rep visitation rates of various pharmaceutical companies.
PatientsMap can be used as a tool for estimating nationwide patient numbers for various diseases across, not only different specialties, but also by hospital tiers and city tiers. It can help you in analyzing the potential of a new drug and also for targeting the appropriate specialties in terms of market research and/or for promotional purposes.

PatientsMap China 2022 data was collected from over 11,000 physicians, covering approximately 400 diseases/conditions. PatientsMap data collection is conducted via online in collaboration with M3.

Outline of PatientsMap 2022 China:
1. Product name: PatientsMap 2022 China
2. Objective: To understand the treatment condition of various specialties for 402 diseases/conditions
3. Methodology: Online survey
4. Survey region: Nationwide
5. Sample size: 11,106 physicians from various departments
6. Fieldwork schedule: 2021 December – 2022 March

Contents of PatientsMap:

• > Total number of patients that they see (per month)
• > Diseases/conditions that they see (402 disease types)
• > Number of patients they see per each disease/condition
• > Number of patients in which they prescribe medications for that disease/condition
• > Diseases in which they wish for new product development
• > Sales rep visitations in the past month (64 manufacturers)
• > Information provision via non-face-to-face methods (64 manufacturers)
• > Demographics
•      - Primary specialty
•      - Area of specialty/sub-specialties
•      - Province and city of the practice
•      - Hospital type and tier level
•      - Number of beds at the hospital
•      - Title
•      - Age range

For more information on PatientsMap, please contact; patientsmap@ssri.com

For more information on PatientsMap CN, please contact (Jane Zhang); zhangjun@ssrichina.com